XASX
CMB
, Last price
AUD
Name
Regeneus Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
-3.53%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-2m
L-61.51%
CFO
-660k
L-84.84%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Key people
Non-Executive Chairman of the Board · since 2019
John Bird
Chief Financial Officer and Operations Officer · since 2014
Graham Vesey
Chief Scientific Officer, Executive Director · since 2014
Sandra McIntosh
Office/Human Resources Manager, Company Secretary
Charlotte Morgan
Head - Laboratory, Research and Development
Duncan Thomson
Head - Veterinary Health
Leo Lee
Chief Executive Officer, Director · since 2019
John C. Chiplin
Non-Executive Independent Director · since 2019
Non-Executive Independent Director · since 2019
Independent Non-Executive Director · since 2015
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||